An update on the pharmacogenetic considerations when prescribing dopamine receptor agonists for Parkinson's disease.

Pedro AyusoFélix Javier Jiménez-JiménezJavier Gómez-TabalesHortensia Alonso-NavarroElena García-MartínJosé A G Agúndez

Published in: Expert opinion on drug metabolism & toxicology (2023)

The pharmacokinetic, pharmacodynamic, and safety profiles of Parkinson's disease drugs do not favor the development of pharmacogenetic tests with a high probability of success. The chances of obtaining ground-breaking pharmacogenetics biomarkers for Parkinson's disease therapy are limited. Nevertheless, additional information on the metabolism of certain drugs, and an analysis of the potential of pharmacogenetics in novel drugs could be of interest.

Keyphrases

primary care
stem cells
healthcare
emergency department
mesenchymal stem cells
uric acid
drug induced
health information
social media
electronic health record